At the JP Morgan Conference in San Francisco, former executive director of Astra Zeneca, newly appointed CEO of BioVitrum, Martin Nicklasson announces launching of clinical trials for a fusion Factor IX Fc molecule with extended product life time allowing a one a week drug administration, thus improving considerably patient quality of life. Phase I & II clinical trials are due to being launched in the US early 2008.
BioVitrum (BVT:SS) is a $536 million market cap biopharmaceutical company.
BioVitrum is currently awaiting results for two Phase II clinical trials for primary care products for the treatment of Glaucoma (retinal hypotension inducer) and for the treatment of Diabetic Neuropathic Pain, for which it claims to be the sole player involved.
The outcome of these trials will determine the future development of the company and surely deserves undivided attention…
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must be logged in to post a comment.